Exchange: NYSE·Updated 07:29 PM EDT
ALC logo

ALCAlcon Inc. - Registered Shares

$69.66
$2.84
(4.25%)
Today
Closed $69.66
$0.00
(0.00%)
After Hours
EarningsAug 10
Mkt Cap$33.95B
Vol1.9M
News
all
press releases
Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?
Alcon's new platforms, lenses and dry eye momentum support growth, but macro pressures, tariffs and fierce competition weigh on its outlook.
Zacks
News Placeholder
More News
News Placeholder
Is COO Stock Attractive as MyDay Gains Meet Asia-Pacific Pressure
COO's MyDay, MiSight and fertility strengths support the long-term case, but Asia-Pacific softness, recall costs and leverage keep the stock in wait-and-see mode.
Zacks
News Placeholder
How COO Is Balancing Premium Lens Growth Against Asia-Pacific Risks?
COO's premium lens, myopia control and fertility momentum support growth, but Asia-Pacific weakness and margin pressure keep the outlook measured.
Zacks
News Placeholder
How COO Is Riding Myopia and Fertility Trends Amid Execution Risks
COO's premium lenses, MiSight and fertility trends support growth, but Asia-Pacific softness, portfolio shifts and cost pressure keep execution in focus.
Zacks
News Placeholder
Alcon (ALC) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
News Placeholder
Reasons to Add Tandem Diabetes Stock to Your Portfolio Right Now
TNDM's pay-as-you-go shift, international expansion and strong liquidity support growth, while macro and reimbursement risks remain.
Zacks
News Placeholder
Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?
Alcon's Surgical and Vision Care units returned to 6% growth in Q1 2026, but tariffs, macro pressure and fierce competition still loom.
Zacks
News Placeholder
Reasons to Retain STE Stock in Your Portfolio for Now
STERIS' Healthcare and AST segments post solid gains and milestones, but FX volatility, tariffs and global macro pressures threaten earnings variability.
Zacks
News Placeholder
EYE Q1 Earnings & Revenues Beat Estimates, Operating Margin Expands
National Vision beats EPS and revenue estimates as comps rise 4.5% and operating margin jumps 320 bps; 2026 guidance reiterated.
Zacks
News Placeholder
PBH Q4 Earnings & Revenues Miss Estimates, Margins Down
Prestige Consumer misses Q4 EPS and revenue estimates as Clear Eyes supply limits and Middle East shipping disruptions pressure sales and margins.
Zacks
<
1
2
...
>

Advertisement|Remove ads.